Extended COPERNICUS Follow-Up on Skin Toxicity and Thrombosis

Wade T. Iams, MD, of Tennessee Oncology, presents extended COPERNICUS follow-up: 274 US participants have received subcutaneous amivantamab plus lazertinib, and 214 enrolled at least 4 months before the data cutoff. Median follow-up reached 8.3 months, 86% remained on study, 56% were 65 years or older, and 22% were 75 or older. The population was 50% White, 27% Asian, and 10% Black, which Luis E. Raez, MD, of Miami Cancer Institute, calls important for confirming the regimen works across groups. For the first 4 months, Dr Raez notes that paronychia fell from 50% in MARIPOSA to 35%, rash from 55% to 25%, and infusion reactions from 55% to about 3%, stressing grade 3 events because treatment is often not restarted after them. Dr Iams reports venous thromboembolism in the first 4 months in 3% of participants vs 23% in MARIPOSA, with no grade 3 or higher bleeding and similar rates across age subgroups.